Switch theme
Sign up to access all valuation multiples
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
1987
23.7K+
LTM Revenue $7.9B
LTM EBITDA $2.0B
$15.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Grifols has a last 12-month revenue of $7.9B and a last 12-month EBITDA of $2.0B.
In the most recent fiscal year, Grifols achieved revenue of $7.7B and an EBITDA of $1.6B.
Grifols expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Grifols valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $7.1B | $7.7B | XXX | XXX | XXX |
| Gross Profit | $2.4B | $2.7B | XXX | XXX | XXX |
| Gross Margin | 34% | 35% | XXX | XXX | XXX |
| EBITDA | $1.3B | $1.6B | XXX | XXX | XXX |
| EBITDA Margin | 18% | 21% | XXX | XXX | XXX |
| Net Profit | $224M | $63.7M | XXX | XXX | XXX |
| Net Margin | 3% | 1% | XXX | XXX | XXX |
| Net Debt | $8.8B | $9.1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Grifols's stock price is EUR 7 (or $8).
Grifols has current market cap of EUR 5.0B (or $5.4B), and EV of EUR 14.2B (or $15.2B).
See Grifols trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15.2B | $5.4B | XXX | XXX | XXX | XXX | $0.73 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Grifols has market cap of $5.4B and EV of $15.2B.
Grifols's trades at 1.9x LTM EV/Revenue multiple, and 7.8x LTM EBITDA.
Analysts estimate Grifols's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Grifols and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $15.2B | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 9.5x | XXX | XXX | XXX |
| P/E | 32.2x | XXX | XXX | XXX |
| P/E/Growth | 0.3x | XXX | XXX | XXX |
| EV/FCF | 26.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGrifols's NTM/LTM revenue growth is 7%
Grifols's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Grifols's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Grifols's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Grifols and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 26% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 27% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 23% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Grifols acquired XXX companies to date.
Last acquisition by Grifols was XXXXXXXX, XXXXX XXXXX XXXXXX . Grifols acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Grifols founded? | Grifols was founded in 1987. |
| Where is Grifols headquartered? | Grifols is headquartered in Spain. |
| How many employees does Grifols have? | As of today, Grifols has 23.7K+ employees. |
| Who is the CEO of Grifols? | Grifols's CEO is Mr. Jose Ignacio Abia Buenache. |
| Is Grifols publicy listed? | Yes, Grifols is a public company listed on MAD. |
| What is the stock symbol of Grifols? | Grifols trades under GRF ticker. |
| When did Grifols go public? | Grifols went public in 2006. |
| Who are competitors of Grifols? | Similar companies to Grifols include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Grifols? | Grifols's current market cap is $5.4B |
| What is the current revenue of Grifols? | Grifols's last 12-month revenue is $7.9B. |
| What is the current EBITDA of Grifols? | Grifols's last 12-month EBITDA is $2.0B. |
| What is the current EV/Revenue multiple of Grifols? | Current revenue multiple of Grifols is 1.9x. |
| What is the current EV/EBITDA multiple of Grifols? | Current EBITDA multiple of Grifols is 7.8x. |
| What is the current revenue growth of Grifols? | Grifols revenue growth between 2023 and 2024 was 9%. |
| Is Grifols profitable? | Yes, Grifols is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
